PET in testicular cancer

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Testicular cancer, a rare malignancy, presents as seminomatous or nonseminomatous types.
• Accurate treatment intensity is challenging due to good overall prognosis and frequent residual masses post-chemotherapy.
• Serum tumor markers are relevant for nonseminomatous tumors but absent in pure seminomas.

Purpose of the Study:

• To evaluate the role of F-18 FDG PET in imaging testicular cancer, focusing on primary tumor detection and post-chemotherapy assessment.
• To determine the efficacy of F-18 FDG PET in differentiating vital from nonvital residual masses.
• To assess the utility of F-18 FDG PET in predicting relapse in advanced testicular cancer.

Main Methods:

• Computed Tomography (CT) is the primary imaging modality for primary testicular tumors.
• F-18 FDG PET is investigated for its role in assessing residual masses after chemotherapy.
• Comparison of PET-CT versus PET alone in testicular cancer imaging was considered.

Main Results:

• F-18 FDG PET has no defined role in imaging primary testicular tumors; CT is preferred.
• F-18 FDG PET is an important tool for assessing chemotherapy success in residual masses, especially in pure seminoma.
• False-negative results are a concern in nonseminomatous tumors due to mature teratomas; PET performs best in seminoma residuals >3 cm.

Conclusions:

• F-18 FDG PET is crucial for evaluating chemotherapy response in testicular cancer residual masses, particularly for pure seminomas.
• CT remains the first-choice for primary tumor imaging, while PET's role is primarily in post-treatment assessment.
• No alternative to F-18 FDG for PET imaging in testicular cancer has been identified; PET-CT superiority over PET alone is unproven.